Fanconi anemia is one of medicine's cruelest diagnoses. A rare inherited disorder that disrupts the body's ability to repair DNA, it causes bone marrow failure — often by age 12 — and carries a dramatically elevated risk of cancer. The current treatments are gruelling: chemotherapy conditioning followed by a stem cell transplant, with severe short and long-term side effects including infertility and increased cancer risk.
Now, Stanford Medicine scientists believe they may be able to treat it **before the baby is born** — before the damage has a chance to begin.
**The Trial**
Stanford is launching a **first-of-its-kind clinical trial** to perform prenatal stem cell transplants for Fanconi anemia (FA) using cells from the mother's own bone marrow. The approach is made possible by a unique window that exists in foetal development: unlike postnatal immune systems, a developing foetus has a natural period of **immune tolerance** — a window during which it may accept donor cells without mounting the rejection responses that complicate adult transplants.
The idea: if healthy stem cells from the mother are introduced during this window, they could engraft and provide the foetus with a functioning source of healthy blood cells — before the disease ever has the chance to destroy the bone marrow.
**Why Now?**
Advances in prenatal diagnosis have made it increasingly possible to detect Fanconi anemia early in pregnancy — sometimes as early as 10–12 weeks via chorionic villus sampling (CVS). This gives doctors a critical early window to act.
Maternal cells have a particular advantage: they're **partially immune-matched** to the foetus (the baby has already been exposed to maternal cells in the womb), making rejection less likely. And using the mother's cells avoids the need for a separate donor match entirely.
**The Science Behind It**
Fanconi anemia is caused by mutations in one of at least **22 FA genes** (most commonly FANCA, FANCC, or FANCG). These genes are involved in the detection and repair of DNA cross-links — a form of DNA damage that occurs naturally and constantly. Without working FA genes, DNA errors accumulate, leading to bone marrow failure and malignant transformation.
The Stanford team, led by researchers in the Division of Fetal and Maternal Medicine, has spent years developing the scientific and logistical framework for this trial. Animal model work has shown promise: engraftment of maternal cells in affected foetuses is feasible, and the treated animals showed improved blood cell production.
**What This Could Mean**
If successful, prenatal treatment for Fanconi anemia could:
- 🩸 **Preserve bone marrow function** from birth, avoiding early failure - 💊 **Eliminate or significantly reduce** the need for post-natal chemotherapy conditioning - 🧬 Allow children to grow up **without a transplant scar** and with better long-term health outcomes - 🔬 Establish a **proof of concept** for prenatal treatment of other genetic blood disorders (sickle cell disease, thalassaemia)
**A Broader Vision**
This trial builds on an emerging frontier of medicine — **in utero intervention**. We have already seen prenatal surgery for conditions like spina bifida (including the landmark CuRe Trial, which used stem cell patches to reverse brain abnormalities before birth). Fanconi anemia represents the next frontier: not correcting a structural defect, but addressing a genetic disorder at the cellular level before the child takes their first breath.
For families who carry the FA gene — and who face the heartbreaking certainty of watching their child develop bone marrow failure — a prenatal treatment option is not just scientific progress. It's hope arriving at the moment it's needed most.
*Sources: Stanford Medicine · med.stanford.edu · March 2026*
